Contact Dermatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Contact Dermatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Contact Dermatitis – Drugs In Development, 2022, provides an overview of the Contact Dermatitis (Dermatology) pipeline landscape.

Contact dermatitis is a type of skin inflammation that occurs when substances touching skin cause irritation or an allergic reaction. Signs and symptoms of contact dermatitis include red rash or bumps, dry, cracked, red patches, which may resemble a burn and pain or tenderness. There are two types of contact dermatitis; irritant and allergic. Irritant dermatitis, the most common type, is caused by contact with acids, alkaline materials such as soaps and detergents, fabric softeners, solvents, or other chemicals. The reaction usually looks like a burn. Allergic contact dermatitis is an itchy skin condition caused by an allergic reaction to allergen. Treatment includes oral corticosteroids and antihistamines to relieve intense itching.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Contact Dermatitis – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Contact Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Contact Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Contact Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Phase III stages comprises 1 molecules, respectively.

Contact Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Contact Dermatitis (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Contact Dermatitis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Contact Dermatitis (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Contact Dermatitis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Contact Dermatitis (Dermatology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Contact Dermatitis (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Contact Dermatitis (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Contact Dermatitis – Overview
Contact Dermatitis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Contact Dermatitis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Contact Dermatitis – Companies Involved in Therapeutics Development
Allakos Inc
Aposcience AG
Edesa Biotech Inc
Hapten Sciences Inc
ILiAD Biotechnologies LLC
NextPhase Therapeutics
Signum Dermalogix Inc
Contact Dermatitis – Drug Profiles
AK-006 – Drug Profile
APO-2 – Drug Profile
Contact Dermatitis – Drug Profile
diflucortolone – Drug Profile
EB-01 – Drug Profile
EB-05 – Drug Profile
HPT-721 – Drug Profile
pertussis [strain BPZE1] vaccine – Drug Profile
SIG-1322 – Drug Profile
Contact Dermatitis – Dormant Projects
Contact Dermatitis – Discontinued Products
Contact Dermatitis – Product Development Milestones
Featured News & Press Releases
Apr 28, 2022: Edesa Biotech reports dermatitis study enrolling faster than expected
Dec 01, 2021: Edesa Biotech marks enrollment milestone in dermatitis study
Mar 09, 2021: Edesa Biotech completes enrollment for interim clinical study milestone
Nov 03, 2020: Edesa Biotech achieves enrollment milestone in dermatitis study
May 15, 2020: Contact dermatitis: potential new treatments with biologic drug
Dec 03, 2019: Edesa Biotech reports positive healthy volunteer data and expands Phase 2b Dermatitis Study to patients with Facial Lesions
Oct 21, 2019: Edesa Biotech enrolls first patient in phase 2b dermatitis study
Jul 25, 2019: Edesa Biotech completes manufacturing for upcoming dermatitis study
Jun 20, 2019: Edesa Biotech receives approval to proceed with U.S. clinical study
Nov 19, 2015: Hapten Sciences to Begin Clinical Trials for Novel Poison Ivy Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Contact Dermatitis, 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Universities/Institutes, 2022
Table 4: Products under Development by Companies, 2022
Table 5: Products under Development by Universities/Institutes, 2022
Table 6: Number of Products by Stage and Target, 2022
Table 7: Number of Products by Stage and Mechanism of Action, 2022
Table 8: Number of Products by Stage and Route of Administration, 2022
Table 9: Number of Products by Stage and Molecule Type, 2022
Table 10: Contact Dermatitis – Pipeline by Allakos Inc, 2022
Table 11: Contact Dermatitis – Pipeline by Aposcience AG, 2022
Table 12: Contact Dermatitis – Pipeline by Edesa Biotech Inc, 2022
Table 13: Contact Dermatitis – Pipeline by Hapten Sciences Inc, 2022
Table 14: Contact Dermatitis – Pipeline by ILiAD Biotechnologies LLC, 2022
Table 15: Contact Dermatitis – Pipeline by NextPhase Therapeutics, 2022
Table 16: Contact Dermatitis – Pipeline by Signum Dermalogix Inc, 2022
Table 17: Contact Dermatitis – Dormant Projects, 2022
Table 18: Contact Dermatitis – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Contact Dermatitis, 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products by Targets, 2022
Figure 4: Number of Products by Stage and Targets, 2022
Figure 5: Number of Products by Mechanism of Actions, 2022
Figure 6: Number of Products by Stage and Mechanism of Actions, 2022
Figure 7: Number of Products by Routes of Administration, 2022
Figure 8: Number of Products by Stage and Routes of Administration, 2022
Figure 9: Number of Products by Molecule Types, 2022
Figure 10: Number of Products by Stage and Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings